Nicox (OTCMKTS:NICXF – Get Free Report) will likely be issuing its resultson Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.4660) per share and revenue of $3.8650 million for the quarter.
Nicox Stock Performance
NICXF stock remained flat at $0.30 on Tuesday. Nicox has a 12 month low of $0.25 and a 12 month high of $0.30. The stock has a 50 day moving average price of $0.30 and a 200 day moving average price of $0.30.
About Nicox
Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.
Recommended Stories
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
